Zhou et al. found that NSCLC with COPD patients with advanced stage receiving anti-programmed cell death 1 (PD1)/PD-L1 immunotherapy obtained a more prolonged progression-free survival (PFS) in contrast to NSCLC without COPD patients [5]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.